Advertisement

Topics

Investors unimpressed as Allergan reports quarterly loss of £902 million but raises guidance

10:49 EDT 3 Aug 2017 | thePharmaLetter

Allergan has slipped by 1.2% in the opening moments of Thursday’s trading to $247.30 after announcing…

Original Article: Investors unimpressed as Allergan reports quarterly loss of £902 million but raises guidance

NEXT ARTICLE

More From BioPortfolio on "Investors unimpressed as Allergan reports quarterly loss of £902 million but raises guidance"

Quick Search
Advertisement